Literature DB >> 17035418

Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?

Kari Roberts, Ioana Preston, Nicholas S Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17035418     DOI： 10.1378/chest.130.4.934

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  3 in total

Review 1.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  Value of impedance cardiography in patients studied for pulmonary hypertension.

Authors:  Adriano R Tonelli; Hassan Alnuaimat; Ning Li; Robin Carrie; Kamal K Mubarak
Journal:  Lung       Date:  2011-05-24       Impact factor: 2.584

3.  The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.

Authors:  Catherine G Billings; Robert Lewis; Judith A Hurdman; Robin Condliffe; Charlie A Elliot; A A Roger Thompson; Ian A Smith; Matthew Austin; Iain J Armstrong; Neil Hamilton; Athanasios Charalampopoulos; Ian Sabroe; Andrew J Swift; Alexander M Rothman; Jim M Wild; Allan Lawrie; Judith C Waterhouse; David G Kiely
Journal:  Pulm Circ       Date:  2019 Apr-Jun       Impact factor: 3.017
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.